In a novel analysis examining the economic impacts of generic semaglutide entering the Canadian market, researchers estimate that a projected price reduction of up to 70% would dramatically increase both the cost-effectiveness and health system affordability of therapy options for patients with type 2 diabetes and high cardiorenal risk.
Please follow and like us:
